❌

Reading view

↗️

FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming

βœ‡Cell Death Discovery nature.com science feeds
By: Fan Jiang Β· Huaju Huang Β· Zhe Dong Β· Lu Zhang Β· Shiti Zhang Β· Mengnan Long Β· Xue Fan Β· Nan Li Β· Hao Ai

Cell Death Discovery, Published online: 07 April 2026; doi:10.1038/s41420-026-03054-6

FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming
  •  
  • ↗️
↗️

Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma

βœ‡Nature - Issue - nature.com science feeds
By: Jiawei Lv Β· Dan-Xue Zheng Β· Jin-Hui Liang Β· Ning Zhang Β· Zu-Lu Ye Β· Xu-Dong Xu Β· Melvin. L. K. Chua Β· Lu-Lu Zhang Β· Zi-Ming Du Β· Zi-Chen Zhang Β· Wen-Fei Li Β· Ling-Long Tang Β· Lei Chen Β· Yan-Ping Mao Β· Rui Guo Β· Yu-Pei Chen Β· Li Lin Β· Yuan Zhang Β· Xu Liu Β· Cheng Xu Β· Zhi-Xuan Li Β· Ling-Xin Xu Β· Pan-Yang Yang Β· Kun Chen Β· Deng Bin Β· Tian-Sheng Gao Β· Jian-Ye Yan Β· Lu-Si Chen Β· Shao Hui Huang Β· Hong-Yun Zhao Β· Shu-Bin Hong Β· Yu-Sheng Jie Β· Hui-Ling Huang Β· Xu-Hua Tang Β· Jing-Ping Yun Β· Li-Zhi Liu Β· Li Tian Β· Hao-Jiang Li Β· Ji-Bin Li Β· Guan-Qun Zhou Β· Jun Ma Β· Ying Sun

Nature, Published online: 11 March 2026; doi:10.1038/s41586-026-10244-w

A clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.
  •  
  • ↗️
There are no more articles
❌